PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend
Australia's Pharmaceutical Benefits Advisory Committee has recommended that the government fund triptorelin, a drug already approved for prostate cancer, for unrestricted use to treat breast cancer, endometriosis, and gender dysphoria. This recommendation follows AstraZeneca's decision to remove Zoladex from the market, which would have left over 7,500 women with breast cancer without an alternative treatment option. The committee met urgently in July to address this public health gap.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- The GuardianTrace: Left
PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend
Australia's Pharmaceutical Benefits Advisory Committee has recommended that the government fund triptorelin, a drug already approved for prostate cancer, for unrestricted use to treat breast cancer, endometriosis, and gender dysphoria. This recommendation follows AstraZeneca's decision to remove Zoladex from the market, which would have left over 7,500 women with breast cancer without an alternative treatment option. The committee met urgently in July to address this public health gap.
Rate outletRead original